RxDoctor Payments DataLook up a doctor →

Diego Maselli Caceres, MD

Pulmonary Disease · San Antonio, TXNPI 1609000421

Payments from drug & device makers

$1,820,744in general payments, 2019–2025

Across 1,295 payments — averaging $1405.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$530K
  • GSK$318K
  • Sanofi$281K
  • Regeneron Healthcare Solutions, Inc.$230K
  • Pfizer$190K
  • Astrazeneca AB$73K
  • plus $200K from 32 others
$20,469in research payments, 2019–2025

Across 17 payments — averaging $1204.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$8K
  • Novartis$8K
  • Sanofi$4K

What the payments were for

  • Consulting fees$356,71423%
  • Speaking & faculty fees$1,031,58367%
  • Travel & lodging$129,1348%
  • Food & beverage$29,5332%
  • Education$2830%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,820,744 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$32,283
Medicare patients
110
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab91$357,727
Fasenra PenBenralizumab56$298,575
TezspireTezepelumab-Ekko66$278,566
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$75,035
NucalaMepolizumab17$71,324
Breztri AerosphereBudesonide/Glycopyr/Formoterol83$66,686
Dupixent SyringeDupilumab14$49,367
Spiriva HandihalerTiotropium Bromide70$45,803
SymbicortBudesonide/Formoterol Fumarate158$39,828
Spiriva RespimatTiotropium Bromide44$31,721
Breo ElliptaFluticasone/Vilanterol46$18,768
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$8,089
Advair DiskusFluticasone Propion/Salmeterol20$6,716
Albuterol Sulfate HfaAlbuterol Sulfate234$6,341
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$5,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$529,529$385,079307 claims
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta$317,787$168,735172 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$11,759$39,81060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →